WO2002076506A1 - Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique - Google Patents
Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique Download PDFInfo
- Publication number
- WO2002076506A1 WO2002076506A1 PCT/FR2002/001101 FR0201101W WO02076506A1 WO 2002076506 A1 WO2002076506 A1 WO 2002076506A1 FR 0201101 W FR0201101 W FR 0201101W WO 02076506 A1 WO02076506 A1 WO 02076506A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- dispersed system
- amino acid
- phase
- dispersed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Definitions
- the present invention relates to the field of pharmaceutical compositions and more particularly the use of lipoamino acids in pharmaceutical compositions as absorption promoters.
- the pulmonary administration has other particularities.
- the constitution of the pulmonary alveoli is very specific and allows the active ingredient to pass directly into the blood, hence the interest of the method.
- the pulmonary administration is therefore distinguished from the administrations at the level of the mucous membranes as previously mentioned, as well as the cutaneous or oral administrations.
- the bioavailability of the active ingredients, when the drugs are administered by these routes, is often limited.
- the gastrointestinal tract is the site of many enzymatic reactions.
- the active ingredients like food, undergo degradations which decrease strongly their concentration.
- An important step in this tract is the passage of the intestinal barrier, called resorption.
- the absorption of the active ingredients depends on their physico-chemical characteristics.
- the active ingredients must cross the different layers of the epidermis. This absorption is a limiting step which is at the origin of a more or less important bioavailability.
- the method of administration by mucosal route that is to say at the level of the mucous membranes directly attached to the skin, has additional characteristics compared to the cutaneous application.
- the pH levels in the mucous membranes are different. Different enzymes that can degrade certain active products are also present.
- a second approach consisted in the administration, directly in a liquid form, of very poorly soluble compounds already solubilized, organized in emulsified systems preferentially of the oil in water type.
- These systems were originally developed to provide parenteral nutrition (Intralipid ® systems of the type, Japanese Patent No. 55 476) have been extended to the oral route, for the solubilization of hydrophobic insoluble active compounds.
- Such systems mainly concern active lipop iles molecules and have the drawback of being difficult to adapt to oral unit presentations.
- Recently, more sophisticated systems, constituting a "pre-concentrate" of surfactants and co-solvent have been developed.
- composition of these systems is not sufficiently adapted to allow the improvement of the absorption of the active molecules.
- the aforementioned systems focus their approach on improving a single parameter. Indeed, some systems only act on the stability of the active ingredients by limiting the destabilizing effect of gastric juices and bile salts. Others focus on improving the solubility or absorption of the active ingredients.
- EP 0552405A1 and EP 0418642A1 are based only on the effect of the lipoamino acid improving the transmembrane passage of the active principle. Such compositions do not exhibit resistance to enzymatic degradations.
- the aim of the present invention is therefore to provide an original system using a compound capable of improving the absorption of the active pharmaceutical ingredients in a pharmaceutical composition, which can be administered in particular by oral route, by transdermal route. , or pulmonary. This improvement is observed in particular when the compound is intimately incorporated with other constituents, thus forming a system according to the present invention.
- the invention relates to the use in a pharmaceutical composition
- a pharmaceutical composition comprising at least one active principle, of at least one lipoamino acid constituted by the association between a fatty acid and an amino acid, the fatty acid comprising from 4 to 40 carbon atoms and the amino acid may be a natural, synthetic or modified amino acid, which may be in native or salified form; the lipoamino acid being either a promoter of intestinal absorption or a promoter of pulmonary absorption, depending on whether the composition is respectively in a galenic form suitable for oral administration or in a galenic form suitable for administration in the lungs.
- Another subject of the invention is a dispersed system for pharmaceutical use comprising:
- the fatty acid associated with the amino acid comprising from 4 to 40 carbon atoms and the amino acid may be a natural, synthetic or modified amino acid, which may be in native or salified form;
- the lipoamino acid being either a promoter of intestinal absorption or a promoter of pulmonary absorption, depending on whether the dispersed system is respectively in a galenic form suitable for oral administration or in a galenic form suitable for administration in the lung.
- the main function of the invention is to improve the absorption of the active ingredients in the body following oral administration, pulmonary administration or skin application.
- the lipoamino acids constituted by the association of an amino acid and a fatty acid comprising from 4 to 40 carbon atoms, preferably from 4 to 22, constitute promoters of absorption particularly advantageous in the case of intestinal absorption or pulmonary absorption.
- These absorption promoters can therefore be used in the context of a pharmaceutical composition intended for oral or pulmonary administration. They can be used directly mixed with the active principle, the pharmaceutical composition then being in the form of a homogeneous phase.
- the dosage form of the composition is suitable for the mode of administration.
- lipoamino acids ci can also be used as absorption promoters in dispersed systems for pharmaceutical use comprising: at least one active principle, at least one of these lipoamino acids, a dispersing phase, a dispersed phase immiscible with the dispersing phase, - at less an emulsifier, and
- dispersed systems comprising these lypoamino acids can be used in particular for oral and pulmonary administration, but also cutaneous and mucosal administrations, that is to say concerning the mucous membranes of the mouth, nose, conjunctiva (inside the eyelids), vagina and rectum.
- the dispersed system For each of these administrations, the dispersed system must be presented in a dosage form appropriate to each administration.
- the dispersed system will be in the form of capsules or syrup.
- the lipoamino acid is used as a promoter of intestinal absorption.
- the dispersed system may in particular be administered in the form of a spray.
- the lipoamino acid is used as an absorption promoter in the lungs.
- the dispersed system may be used in the form of a cream or gel.
- the lipoamino acid is used as an absorption promoter in these mucous membranes.
- the amino acid constituting the lipoamino acid is included in the group of synthetic or modified natural amino acids.
- aspartic acid glutamic acid, alanine, arginine, carnitine, choline, cysteine, glycine, histidine , Isoleucine, leucine, lysine, methionine, phenylalanine, proline, ornithine, taurine, threonine, tryptophan, tyrosine, serine or valine.
- lipoamino acid salts are intended to mean any derivative resulting from the ionic interaction between an organic or inorganic molecule with one or more reactive functions carried by the lipoamino acid.
- the lipoamino acid is present in a proportion of between 0.01 and 50% by weight.
- the lipophilic phase comprises at least one lipophilic compound of natural, synthetic or modified origin.
- a lipophilic compound of natural, synthetic or modified origin By way of example, we can cite, vegetable and mineral oils, waxes, fatty acids and their derivatives, fatty alcohols and their derivatives, cholesterol and its derivatives, lecit ines, phospholipids, derivatives of condensation of fatty substances with sugars, polyols and ethylene oxide or propylene oxide.
- This lipophilic compound preferably consists of a free or esterified fatty acid, present in a proportion of between 0.1 to 70% by weight. Depending on its composition, this lipophilic phase occurs in a liquid, semi-solid or solid state at room temperature.
- the hydrophilic phase comprises at least one hydrophilic compound of natural, synthetic or modified origin.
- hydrophilic compound of natural, synthetic or modified origin By way of example, mention may be made of water, alcohols, hydrophilic compounds such as derivatives of propylene glycol, glycerol, glycols, polyols, polymers derived from the condensation of ethylene oxide or propylene oxide, hydrocolloids.
- this hydrophilic phase occurs in a liquid, semi-solid or solid state at room temperature.
- the dispersed system comprises at least one emulsifying agent, of natural, synthetic or modified origin.
- Examples 1 to 8 describe formulations of dispersed systems comprising one or more lipoamino acids (in bold) and their preparation process. These dispersed systems are more particularly of the water in oil type (Examples 2 to 7), that is to say with a hydrophilic dispersed phase and a lipophilic dispersing phase. While Example 8 describes an oil-in-water dispersed system, that is to say with a lipophilic dispersed phase and a hydrophilic dispersing phase.
- compositions were the subject of an in vitro permeation study. These are systems including progesterone, aciclovir and ciclosporin A.
- lipid solution consisting of a mixture of phospholipids
- composition of the medium can vary depending on the physicochemical characteristics of the molecule.
- Permeation expresses an amount of active principle which diffuses through a membrane per unit of area and time ( ⁇ g / cm 2 / h).
- Example 1 Process for the preparation of dispersed systems
- Example 2 to 7 The dispersed systems presented in Examples 2 to 7 are prepared according to the principle of a reverse emulsion.
- Example 8 is in turn prepared according to the principle of a direct emulsion.
- the two phases are prepared independently:
- a hydrophilic phase consisting of at least one hydrophilic compound and of the active ingredient (s), heated between 40 and 80 ° C.
- a lipophilic phase consisting of at least one lipid compound, of the hydrophilic / lipophilic emulsifier or surfactant, generally a vegetable oil, natural or modified, heated between 40 and 80 ° C. Depending on the melting temperatures of the phases, we preferentially obtain
- Example 2 Dispersed system comprising an anti-acne compound, isotretinoline - Isopropyl myristate 31.5%
- Example 4 A dispersed system intended for the transdermal route, comprising a hormone, progesterone.
- Soybean oil 31 4% Oleic acid 10% lauroyl methionine 5%
- Dispersed system for the oral route comprising an antiviral, aciclovir
- Example 6 Dispersed system for the topical route, comprising an antiviral, aciclovir. - 1.8% oleic acid
- Example 7 Dispersed system intended for the oral route, comprising an immunosuppressant, ciclosporin A
- Oil-in-water dispersed system for the oral route comprising an immunosuppressant, ciclosporin A
- a lipoamino acid preferably formulated in a dispersed system makes it possible to improve the transmembrane passage of an active principle and its absorption.
- a lipoamino acid preferably formulated in a dispersed system makes it possible to improve the transmembrane passage of an active principle and its absorption.
- Such a compound can therefore be used as a promoter of intestinal or pulmonary absorption. It can also be used in a dispersed system while retaining its absorption promoter properties.
- lipoaminnoacids come to organize themselves at the hydrophilic-lipophilic interface of emulsions because of their amphihpile property.
- the nature of the amino acid (free or basic acid function) involved in the lipoamino acid can promote the formation of ionic bonds with functions carried by the active ingredients, which makes it possible to strengthen the stability of the system, but also to contribute to the solubilization of the active ingredients.
- dispersed system avoids the destabilizing action of pancreatic lipases and digestive juices, leaks and degradation of active ingredients. Indeed, and in some cases, the oily phase external of the dispersed system prevents the migration of gastrointestinal juices through it, to degrade the active ingredient and destabilize the dispersed system.
- the cohesion of these dispersed systems allows intimate contact with the intestinal, pulmonary or dermal cells, which improves the availability of the discontinuous phase, in which the active principle is organized.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/473,312 US20040147578A1 (en) | 2001-03-28 | 2002-03-28 | Use of lipoaminoacids as absorption promoters in a pharmaceutical composition |
EP02724387A EP1372730A1 (fr) | 2001-03-28 | 2002-03-28 | Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique |
CA002441824A CA2441824A1 (fr) | 2001-03-28 | 2002-03-28 | Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0104187A FR2828101A1 (fr) | 2001-03-28 | 2001-03-28 | Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteurs d'absorption et systeme disperse a usage pharmaceutique contenant de tels composes |
FR01/04187 | 2001-03-28 | ||
FR0107051A FR2828102B1 (fr) | 2001-03-28 | 2001-05-30 | Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes |
FR01/07051 | 2001-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002076506A1 true WO2002076506A1 (fr) | 2002-10-03 |
Family
ID=26212940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/001101 WO2002076506A1 (fr) | 2001-03-28 | 2002-03-28 | Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040147578A1 (fr) |
EP (1) | EP1372730A1 (fr) |
CA (1) | CA2441824A1 (fr) |
FR (1) | FR2828102B1 (fr) |
WO (1) | WO2002076506A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20080551A1 (it) * | 2008-10-15 | 2010-04-16 | Univ Catania | Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici. |
WO2011141685A2 (fr) | 2010-05-14 | 2011-11-17 | Physica Pharma Sas | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants |
WO2012114054A1 (fr) | 2011-02-24 | 2012-08-30 | Physica Pharma Sas | Compositions pharmaceutiques à action locale administrables par application cutanée |
WO2012114051A1 (fr) | 2011-02-24 | 2012-08-30 | Physica Pharma Sas | Compositions pharmaceutiques administrables par voie cutanée et destinées au traitement local de la dermatite atopique canine |
WO2014060512A1 (fr) * | 2012-10-17 | 2014-04-24 | Novo Nordisk Health Care Ag | Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2834215B1 (fr) * | 2001-12-27 | 2004-07-16 | Physica | Composes amphiphiles a usage pharmaceutique ou cosmetique |
CN101160323A (zh) * | 2005-04-15 | 2008-04-09 | 拉帕波特家族医学科学研究所 | 用于治疗mcp-1/ccr2相关疾病的分子及其使用方法 |
EP2696847A1 (fr) * | 2011-04-14 | 2014-02-19 | Novo Nordisk A/S | Acides aminés acylés par un acide gras pour l'administration de peptides par voie orale |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
MX365818B (es) | 2011-11-23 | 2019-05-30 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo hormonal de combinacion naturales. |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6285447B2 (ja) * | 2012-10-17 | 2018-02-28 | ノヴォ ノルディスク アー/エス | 経口ペプチド送達用の脂肪酸アシル化d−アミノ酸 |
EP2908844A1 (fr) * | 2012-10-17 | 2015-08-26 | Novo Nordisk A/S | Acides aminés acylés par un acide gras pour l'administration de peptides par voie orale |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2015162195A1 (fr) * | 2014-04-23 | 2015-10-29 | Novo Nordisk A/S | Acides aminés acylés par un acide gras pour l'administration de peptides par voie orale |
CA2947767A1 (fr) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Formulations d'hormones substitutives combinees naturelles et traitement hormonal substitutif |
JP2017523138A (ja) * | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 経皮クリーム |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5788126A (en) * | 1980-11-19 | 1982-06-01 | Kyoto Yakuhin Kogyo Kk | Agent for promoting peroral and transvaginal absorption and preparation containing the same |
EP0093551A2 (fr) * | 1982-04-30 | 1983-11-09 | Ajinomoto Co., Inc. | Composition pharmaceutique |
JPS5980326A (ja) * | 1982-10-29 | 1984-05-09 | Kobayashi Kooc:Kk | W/o/w型エマルジヨンの製造方法 |
EP0418642A1 (fr) * | 1989-09-11 | 1991-03-27 | Teikoku Seiyaku Kabushiki Kaisha | Préparation transvaginale hautement absorbable contenant un peptide biologiquement actif |
EP0552405A1 (fr) * | 1992-01-24 | 1993-07-28 | LINTEC Corporation | Stimulateur d'absorption percutanée, pansement et méthode pour la stimulation de l'absortion percutanée |
JPH05310552A (ja) * | 1992-05-13 | 1993-11-22 | Kanebo Ltd | 皮膚外用剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4442090A (en) * | 1980-11-09 | 1984-04-10 | Kyoto Yakuhin Kogyo Kabushiki Kaisha | Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use |
US4837026A (en) * | 1985-10-03 | 1989-06-06 | Rajakhyaksha Vithal J | Transdermal and systemic preparation and method |
ATE333867T1 (de) * | 1994-03-18 | 2006-08-15 | Shire Lab Inc | Emulgierte arzneistoffabgabesysteme |
-
2001
- 2001-05-30 FR FR0107051A patent/FR2828102B1/fr not_active Expired - Fee Related
-
2002
- 2002-03-28 US US10/473,312 patent/US20040147578A1/en not_active Abandoned
- 2002-03-28 CA CA002441824A patent/CA2441824A1/fr not_active Abandoned
- 2002-03-28 EP EP02724387A patent/EP1372730A1/fr not_active Withdrawn
- 2002-03-28 WO PCT/FR2002/001101 patent/WO2002076506A1/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5788126A (en) * | 1980-11-19 | 1982-06-01 | Kyoto Yakuhin Kogyo Kk | Agent for promoting peroral and transvaginal absorption and preparation containing the same |
EP0093551A2 (fr) * | 1982-04-30 | 1983-11-09 | Ajinomoto Co., Inc. | Composition pharmaceutique |
JPS5980326A (ja) * | 1982-10-29 | 1984-05-09 | Kobayashi Kooc:Kk | W/o/w型エマルジヨンの製造方法 |
EP0418642A1 (fr) * | 1989-09-11 | 1991-03-27 | Teikoku Seiyaku Kabushiki Kaisha | Préparation transvaginale hautement absorbable contenant un peptide biologiquement actif |
EP0552405A1 (fr) * | 1992-01-24 | 1993-07-28 | LINTEC Corporation | Stimulateur d'absorption percutanée, pansement et méthode pour la stimulation de l'absortion percutanée |
JPH05310552A (ja) * | 1992-05-13 | 1993-11-22 | Kanebo Ltd | 皮膚外用剤 |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Week 188425, Derwent World Patents Index; AN 1984-154752, XP002207780 * |
DATABASE WPI Week 199401, Derwent World Patents Index; AN 1994-002223, XP002207779 * |
PATENT ABSTRACTS OF JAPAN vol. 006, no. 174 (C - 123) 8 September 1982 (1982-09-08) * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20080551A1 (it) * | 2008-10-15 | 2010-04-16 | Univ Catania | Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici. |
WO2011141685A2 (fr) | 2010-05-14 | 2011-11-17 | Physica Pharma Sas | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants |
FR2959936A1 (fr) * | 2010-05-14 | 2011-11-18 | Physica Pharma | Composition nasales a visee systemique a base de cocoyl proline ou d 'au moins un de ses constituants |
WO2011141685A3 (fr) * | 2010-05-14 | 2012-08-02 | Physica Pharma Sas | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants |
WO2012114054A1 (fr) | 2011-02-24 | 2012-08-30 | Physica Pharma Sas | Compositions pharmaceutiques à action locale administrables par application cutanée |
WO2012114051A1 (fr) | 2011-02-24 | 2012-08-30 | Physica Pharma Sas | Compositions pharmaceutiques administrables par voie cutanée et destinées au traitement local de la dermatite atopique canine |
WO2014060512A1 (fr) * | 2012-10-17 | 2014-04-24 | Novo Nordisk Health Care Ag | Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance |
Also Published As
Publication number | Publication date |
---|---|
CA2441824A1 (fr) | 2002-10-03 |
FR2828102B1 (fr) | 2004-07-09 |
EP1372730A1 (fr) | 2004-01-02 |
US20040147578A1 (en) | 2004-07-29 |
FR2828102A1 (fr) | 2003-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002076506A1 (fr) | Utilisation de lipoaminoacides comme promoteurs d'absorption dans une composition pharmaceutique | |
JP3487860B2 (ja) | 逆ミセル(l2)構造または正常ミセル(l1)構造を形成する制御放出組成物 | |
Alkilani et al. | Nanoemulsion-based film formulation for transdermal delivery of carvedilol | |
LU87586A1 (fr) | Compositions pharmaceutiques a base de cyclosporins | |
CA2451855A1 (fr) | Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal | |
Lee et al. | Microemulsion-based hydrogel formulation of itraconazole for topical delivery | |
Ita et al. | Percutaneous delivery of antihypertensive agents: advances and challenges | |
FR2553661A1 (fr) | Nouvelles microemulsions pharmaceutiquement acceptables | |
WO2014199105A1 (fr) | Microparticules avec des cyclodextrines à double niveau d'encapsulation | |
EP1244427B1 (fr) | Compositions pharmaceutiques destinees a une administration par voie orale | |
Kamani et al. | Phospholipid based ultra-deformable nanovesicular gel for transcutaneous application: QbD based optimization, characterization and pharmacodynamic profiling | |
EP0726760B1 (fr) | Formulation auto-emulsionnable formant une huile dans eau | |
EP1478402A1 (fr) | Preparation pour composees sensibles a l'oxydation et son procede de fabrication | |
WO1993009805A1 (fr) | Composition lipidique polaire d'origine vegetale | |
FR2828101A1 (fr) | Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteurs d'absorption et systeme disperse a usage pharmaceutique contenant de tels composes | |
RU2810897C2 (ru) | Фармацевтические составы аналогов циклоспорина | |
WO2003055528A2 (fr) | Composes amphiphiles a usage pharmaceutique ou cosmetique | |
EP3302421B1 (fr) | Compositions comprenant au moins un principe actif disperse et des microcapsules lipidiques | |
EP4153322A1 (fr) | Conjugue terpenique de couplage | |
WO2024100219A1 (fr) | Principes actifs et leur utilisation pour retablir la permeabilite intestinale et/ou prevenir ou lutter contre des maladies multifactorielles | |
WO2024165165A1 (fr) | Système d'émulsification huile dans l'eau à base de cannabinoïdes pour administration sublinguale et buccale ciblant des récepteurs endocannabinoïdes | |
WO2010067035A1 (fr) | Procede de fabrication d'une formulation et utilisation pour la delivrance de medicaments polaires | |
EP4337262A1 (fr) | Compositions de conjugues poly-lysine et de micelles et/ou de copolymeres de poly-lysine | |
RU2301679C2 (ru) | Фармацевтический препарат, содержащий циклоспорин, и его применение | |
EP2678024A1 (fr) | Compositions pharmaceutiques administrables par voie cutanée et destinées au traitement local de la dermatite atopique canine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2441824 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002724387 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002724387 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10473312 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |